US Pharma MarketingFuture of AstraZeneca’s gene silencer in heart disease uncertain after trial failure
AstraZeneca and Ionis Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals:…
MUNICH — The surprise failure of a high-profile study of AstraZeneca and Ionis Pharmaceuticals’ Wainua can be attributed to patients in the trial also taking a Pfizer drug for the same condition, the head of the ...
Source: Endpoints News